ArticlePloS one2019
Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Healthcare resource use and costs of varicella and its complications: A systematic literature review.Human vaccines & immunotherapeutics · 2023Pooled it
- Pooled it
- Economic burden of varicella in Europe in the absence of universal varicella vaccination.BMC public health · 2021Pooled it
- Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model.PharmacoEconomics - open · 2026Article
- Demographical and Clinical Characteristics, Risk Factors, and Prognosis of Adult Patients with Herpes Zoster in Türkiye: A Retrospective, Multi-Center Study (VARICOMP-Adult Study).Infectious disease reports · 2025Article
- Validating the Predictions of a Dynamic Transmission Model Using Real-World Data from a Universal Varicella Vaccination Program in Germany.Journal of market access & health policy · 2025Article
- The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years (2020-2070).Scientific reports · 2024Article
- Herpes Zoster Burden of Disease and Clinical Management in Turkey: A Comprehensive Literature Review.Infectious diseases and therapy · 2023Review
- National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis.The Lancet regional health. Western Pacific · 2023Article
- Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness.PLOS global public health · 2023Article
- The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study.Human vaccines & immunotherapeutics · 2022Article
- Article
- The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia.Journal of health economics and outcomes research · 2022Article
- Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.PloS one · 2021Article
- Effects of immunization program on morbidity and mortality rates ofvaccine-preventable diseases in TurkeyTurkish journal of medical sciences · 2020Article
- Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective.Human vaccines & immunotherapeutics · 2020Article
- The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies.ClinicoEconomics and outcomes research : CEOR · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2013, Turkey introduced one-dose universal varicella vaccination (UVV) at 12 months of age. Inclusion of a second dose is being considered.
methodsWe developed a dynamic transmission model to evaluate three vaccination strategies: single dose at 12 months (1D) or second dose at either 18 months (2D-short) or 6 years of age (2D-long). Costs and utilization were age-stratified and separated into inpatient and outpatient costs for varicella and herpes zoster (HZ). We ran the model including and excluding HZ-related costs and impact of exogenous boosting.
resultsFive years post-introduction of UVV (1D), the projected varicella incidence rate decreases from 1,674 cases pre-vaccine to 80 cases/100,000 person-years. By 25 years, varicella incidence equilibrates at 39, 12, and 16 cases/100,000 person-years for 1D, 2D-short, and 2D-long strategies, respectively, using a highly effective vaccine. With or without including exogenous boosting impact and/or HZ-related costs and health benefits, the 1D strategy is least costly, but 2-dose strategies are cost-effective considering a willingness-to-pay threshold equivalent to the gross domestic product. The model predicted a modest increase in HZ burden during the first 20-30 years, after which time HZ incidence equilibrates at a lower rate than pre-vaccine.
conclusionsOur findings support adding a second varicella vaccine dose in Turkey, as doing so is highly cost-effective across a wide range of assumptions regarding the burden associated with varicella and HZ disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.